Cell culture

Automation software developers Celltrio and Biosero will integrate Biosero’s Green Button Go Automation Scheduling Software with Celltrio’s RoboCell Automation Platform to accelerate cell line culturing and harvesting processes, including cryogenic storage, into a new end-to-end system. The aim is that Green Button Go will accelerate the cell culture and harvesting process, by as much as […]

CN Bio has received a grant from Innovate UK to develop human-relevant single and multi-organ microphysiological systems (MPS) to advance investigations into SARS-CoV-2 infection and advance 3D lung cell culture models to accelerate drug discovery. The grant will be spent developing and testing advanced cell culture models that represent different regions of the lung and […]

CN Bio is a cell culture company whose mission is to transform the way human-relevant pre-clinical data is generated by developing the most complete model of the human ‘body-on-a-chip’ in the laboratory.  Achieving this is what drives the company’s future initiatives, CEO Dr David Hughes told Lu Rahman. CN Bio hit its first major milestone […]

Ground-breaking research at Teesside University using artificial intelligence to predict the growth rate of living organisms could have far-reaching consequences in the field of pharmaceuticals and medical diagnostics. A team of researchers led by Dr Claudio Angione from the University’s School of Computing, Engineering and Digital Technology looked at how computational modelling techniques could be […]

By Dr Ross Macdonald Cell-based therapies are being widely recognised for their potential to treat a variety of medical conditions, but they face major obstacles toward commercialisation. Traditionally, they have been difficult and expensive to make in large quantities. Biopharmaceutical companies must develop manufacturing solutions that will enable them to efficiently and reproducibly create the […]

The CELL CULTURE innovations increasing drug discovery success By Helen Stewart-Miller and Abby George Volume 21 Issue 3 – Summer 2020 ‘Fail early, fail fast’ has been a mantra in the pharmaceutical industry for several years and directly impacts the overall strategy of many drug discovery and development programmes. Yet, despite the drive to fail […]

Guidelines & Recommendations For Analyzing and Interpreting GPCR Second Messenger Data Sponsored by CisBio The question of choosing which methods to use for analyte quantification (signal vs concentration determination, parameters, and format) continues to generate heated debates and divergent understanding. Today, there is still a communication gap between researchers depending on their field of expertise […]

Stem Cell Differentiation By Dr Lilian Hook Stem cells are extraordinary cells, capable of both self-renewal and differentiation to mature somatic cells in vivo and in vitro (1,2). They have many features and advantages which could revolutionise drug development and healthcare applications. Stem cells offer a limitless, consistent supply of physiologically relevant cells from validated […]

Phenotypic Drug Discovery With High Content Screening Sponsored by PerkinElmer Early drug discovery used to be conducted mainly in a target-agnostic fashion, focusing on qualitative readouts from a living system – cells, tissue, or organisms – and asking the question, did this entity affect the phenotype? Target Based or Phenotypic Screening? With the rise of […]

Image: ThisisEngineering RAEng CPI, MicrofluidX and the Cell and Gene Therapy Catapult (CGT Catapult) have collaborated in a project to develop bioprocessing technology for the rapid scale-up of cell and gene therapies. The technology has the potential to overcome a major bottleneck in the development of these novel treatments, and reduce the time and costs […]